As of 2026-04-05, the Intrinsic Value of Eupraxia Pharmaceuticals Inc (EPRX.TO) is -3.24 CAD. This EPRX.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 9.95 CAD, the upside of Eupraxia Pharmaceuticals Inc is -132.55%.
Based on its market price of 9.95 CAD and our intrinsic valuation, Eupraxia Pharmaceuticals Inc (EPRX.TO) is overvalued by 132.55%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.24 - -3.24 | -3.24 | -132.55% |
| P/E | 9.98 - 9.98 | 9.98 | 0.3% |
| DDM - Stable | (2.94) - (5.79) | (4.37) | -143.9% |
| DDM - Multi | (0.04) - (0.06) | (0.05) | -100.5% |
| Market Cap (mil) | 592.52 |
| Beta | 1.51 |
| Outstanding shares (mil) | 59.55 |
| Enterprise Value (mil) | 511.96 |
| Market risk premium | 5.10% |
| Cost of Equity | 16.74% |
| Cost of Debt | 5.00% |
| WACC | 10.87% |